170 related articles for article (PubMed ID: 8926796)
21. Prostate cancer: a review of common underwriting problems, Part 1.
Richie RC; Swanson JO
J Insur Med; 2004; 36(3):242-54. PubMed ID: 15495440
[TBL] [Abstract][Full Text] [Related]
22. Screening for prostate cancer. Why can't the clock be turned back?
Addy DP
BMJ; 1998 Jun; 316(7148):1904. PubMed ID: 9669858
[No Abstract] [Full Text] [Related]
23. Early detection of prostate cancer: is PSA a reliable option?
Okihara K; Babaian RJ
Tex Med; 2001 Feb; 97(2):59-62. PubMed ID: 11233061
[TBL] [Abstract][Full Text] [Related]
24. The value of PSA screening.
Dykers JR
N C Med J; 1994 Jan; 55(1):7-8. PubMed ID: 7510044
[No Abstract] [Full Text] [Related]
25. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
[TBL] [Abstract][Full Text] [Related]
26. [Prostate cancer screening using prostate-specific antigen (PSA) determinations in plasma. National Academy of Medicine].
Bourel M; Ardaillou R;
Bull Acad Natl Med; 2003; 187(5):985-95. PubMed ID: 14979060
[TBL] [Abstract][Full Text] [Related]
27. Progress in the control of prostate cancer in Rhode Island, 1987-2000.
Chiaverini L; Fulton JP; Darcy DM
Med Health R I; 2002 Sep; 85(9):291-3. PubMed ID: 12371217
[No Abstract] [Full Text] [Related]
28. Prostate cancer--more information and more questions.
Dall'Era M; Carroll PR
J Urol; 2007 May; 177(5):1607-8. PubMed ID: 17437768
[No Abstract] [Full Text] [Related]
29. [Cancer of the prostate: advances in the use of PSA and its derived indices--new tumor markers].
Zlotta A; Schulman C
Rev Med Brux; 1999 Sep; 20(4):A201-5. PubMed ID: 10523893
[TBL] [Abstract][Full Text] [Related]
30. Why PSA testing does have value.
Kirby M
Practitioner; 1997 Jul; 241(1576):363. PubMed ID: 9425708
[No Abstract] [Full Text] [Related]
31. Editorial comment: factor that influence serum prostate-specific antigen levels in terms of maintaining quality within a PSA screening system.
Ito K
Eur Urol; 2007 Sep; 52(3):714. PubMed ID: 17849514
[No Abstract] [Full Text] [Related]
32. Informing patients about the PSA test: a new requirement.
Wise P; Duke K
West J Med; 1998 Sep; 169(3):166-7. PubMed ID: 9771156
[No Abstract] [Full Text] [Related]
33. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
Barry MJ; Mulley AJ
J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
[No Abstract] [Full Text] [Related]
34. PSA screening: a view from the front lines. North York General-Branson Practice-Based Small Group.
Greiver M; Rosen N
CMAJ; 2000 Mar; 162(6):789-90. PubMed ID: 10750465
[No Abstract] [Full Text] [Related]
35. PSA and prostate cancer screening: the challenge of the new millennium.
Bjartell A
Eur Urol; 2007 Nov; 52(5):1284-6. PubMed ID: 17720305
[No Abstract] [Full Text] [Related]
36. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
Roobol MJ; Roobol DW; Schröder FH
Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
[TBL] [Abstract][Full Text] [Related]
37. Beyond PSA: utility of novel tumor markers in the setting of elevated PSA.
Lin DW
Urol Oncol; 2009; 27(3):315-21. PubMed ID: 19414121
[TBL] [Abstract][Full Text] [Related]
38. Advances in the application of prostate-specific antigen in the detection of early-stage prostate cancer.
Kamoi K; Babaian RJ
Semin Oncol; 1999 Apr; 26(2):140-9. PubMed ID: 10597725
[TBL] [Abstract][Full Text] [Related]
39. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker.
Hernández J; Thompson IM
Cancer; 2004 Sep; 101(5):894-904. PubMed ID: 15329895
[TBL] [Abstract][Full Text] [Related]
40. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
Roobol MJ; Grenabo A; Schröder FH; Hugosson J
J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
